Cases & Deals

Neurocrine Biosciences expands patent portfolio related to use of INGREZZA (valbenazine) in treatment of abnormal movement disorders

Clients Neurocrine Biosciences, Inc.

Jones Day represents Neurocrine Biosciences, Inc. in prosecution of patent portfolio directed to use of INGREZZA (valbenazine) in treatment of abnormal movement disorders, including tardive dyskenisia and Tourette’s syndrome.